Show simple item record

dc.contributor.authorGee, C
dc.contributor.authorFleuret, C
dc.contributor.authorWilson, A
dc.contributor.authorLevine, D
dc.contributor.authorElhusseiny, R
dc.contributor.authorMuls, A
dc.contributor.authorCunningham, D
dc.contributor.authorKohoutova, D
dc.date.accessioned2022-02-23T09:41:39Z
dc.date.available2022-02-23T09:41:39Z
dc.date.issued2021-12-10
dc.identifier.citationCancers, 2021, 13 (24)en_US
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5030
dc.identifier.eissn2072-6694en_US
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers13246213en_US
dc.identifier.doi10.3390/cancers13246213
dc.description.abstractThe aim was to establish prevalence of bile acid malabsorption (BAM) and management in patients who underwent treatment for malignancy. Retrospective evaluation of data in patients seen within six months (August 2019-January 2020) was carried out. Demographic, nuclear medicine (Selenium Homocholic Acid Taurine (SeHCAT) scan result), clinical (previous malignancy, type of intervention (medication, diet), response to intervention) and laboratory (vitamin D, vitamin B12 serum levels) data were searched. In total, 265 consecutive patients were reviewed. Out of those, 87/265 (33%) patients (57 females, 66%) were diagnosed with BAM. Mean age was 59 +/- 12 years. The largest group were females with gynaecological cancer (35), followed by haematology group (15), colorectal/anal (13), prostate (9), upper gastrointestinal cancer (6), another previous malignancy (9). Severe BAM was most common in haematology (10/15; 67%) and gynaecological group (21/35; 60%). Medication and low-fat diet were commenced in 65/87 (75%), medication in 10/87 (11%), diet in 6/87 (7%). Colesevelam was used in 71/75 (95%). Symptoms improved in 74/87 (85%) patients. Vitamin D insufficiency/deficiency was diagnosed in 62/87 (71%), vitamin B12 deficiency in 39/87 (45%). BAM is a common condition in this cohort however treatments are highly effective.en_US
dc.formatElectronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleBile Acid Malabsorption as a Consequence of Cancer Treatment: Prevalence and Management in the National Leading Centre.en_US
dc.typeJournal Article
dcterms.dateAccepted2021-12-08
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.3390/cancers13246213en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2021-12-10
dc.relation.isPartOfCancersen_US
pubs.issue24en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume13en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMedicine (RMH Smith Cunningham)
dc.contributor.icrauthorCunningham, Daviden_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/